Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. (MNOV) is a clinical-stage biopharmaceutical company advancing novel therapies for neurodegenerative disorders, fibrotic diseases, and inflammatory conditions. This page serves as the definitive source for verified corporate developments, offering investors and researchers timely access to essential information.
Find comprehensive coverage of MNOV's clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes updates on lead candidates MN-166 (ibudilast) and MN-001 (tipelukast), patent developments, and collaborative research initiatives with academic institutions.
Key content categories include clinical program updates, FDA communications, intellectual property announcements, and financial disclosures. All materials are sourced directly from company filings and official statements to ensure accuracy.
Bookmark this page for streamlined tracking of MNOV's progress in developing small-molecule therapeutics. Check regularly for updates on pipeline advancements in ALS, multiple sclerosis, and fibrotic disease research.
MediciNova (NASDAQ:MNOV) announced on November 18, 2025 the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova’s drug development programs and will lead the Scientific Advisory Board upon its formation.
Dr. Breder brings over two decades of regulatory and clinical experience, including more than a decade at the FDA as Medical Officer and Lead Medical Officer, involvement in NDA review and safety analysis training, and participation in reviews and initial approvals for therapies targeting ALS, myasthenia gravis, and Duchenne muscular dystrophy. He holds an MD and PhD from the University of Chicago and completed clinical training at Johns Hopkins Hospital.
MediciNova (NASDAQ:MNOV) announced on November 6, 2025 that it won the Contract Research and Development Innovation Award at the Fifth Annual BioTech Breakthrough Awards.
The award recognizes MediciNova's work advancing MN-166 (ibudilast), its lead small-molecule candidate in development for multiple neurological diseases including ALS. The company noted ongoing progress in the Phase 2/3 COMBAT-ALS trial and said the recognition highlights its focus on neuroinflammation modulation and neuroprotection as a potential disease-modifying approach.
MediciNova (NASDAQ:MNOV) announced completion of patient enrollment in the Phase 2 MN-001-NATG-202 trial of MN-001 (tipelukast) for hypertriglyceridemia and NAFLD due to Type 2 diabetes.
The multi-center, randomized, double-blind, placebo-controlled study randomizes patients 1:1 to 500 mg/day MN-001 or placebo for 24 weeks. Co-primary endpoints are change in liver fat by CAP score and change in fasting serum triglycerides at Week 24. Secondary endpoints include safety, tolerability, and changes in HDL-C, LDL-C, and total cholesterol. Patient recruitment is closed and top-line data are expected by summer 2026.
MediciNova (NASDAQ:MNOV) announced a peer-reviewed study published Oct 30, 2025 showing that MN-002, the primary metabolite of investigational tipelukast (MN-001), enhanced cholesterol efflux in macrophages by upregulating transport proteins ABCA1 and ABCG1. The research, conducted with a Japanese academic group and published in the Journal of Atherosclerosis and Thrombosis, suggests a novel mechanism of action and a potential therapeutic strategy for atherosclerosis and metabolic disorders.
MediciNova said MN-001 is an oral small molecule with anti-inflammatory and anti-fibrotic properties, prior clinical studies showed improved serum lipid profiles in NAFLD and hypertriglyceridemia patients, and a randomized double-blind Phase 2 study in hypertriglyceridemia, type 2 diabetes, and NAFLD is nearing enrollment completion.
MediciNova (NASDAQ: MNOV) will present a corporate overview at the LD Micro Main Event XIX in San Diego on Monday, October 20, 2025 at 1:30 PM PT. Presenters are Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer.
A live webcast will be available via the company's investor relations website and a replay will be archived for 90 days. The presenters will be available for one-on-one meetings during the conference (October 19–22, 2025).
MediciNova (NASDAQ:MNOV) has completed patient enrollment in its Phase 2b/3 COMBAT-ALS clinical trial evaluating MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis (ALS) treatment. The study has successfully randomized 234 patients across sites in the United States and Canada.
The trial is designed as a randomized, double-blind, placebo-controlled study with a 12-month treatment period followed by a 6-month open-label extension. The primary endpoint focuses on the Combined Assessment of Function and Survival (CAFS), with top-line data expected by end of 2026.
MN-166 has received Orphan Drug and Fast Track Designations from the FDA and Orphan Designation from the EMA, having shown promising results in earlier studies.
MediciNova (NASDAQ:MNOV) announced that its Phase 2b/3 COMBAT-ALS clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients will be featured in a poster presentation at the 36th International Symposium on ALS/MND. The symposium will take place from December 5-7, 2025 in San Diego, CA.
The presentation, titled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Baseline Characteristics," has been assigned Paper Number 228 and falls under the Clinical Trial and Trial Design theme.
MediciNova (NASDAQ: MNOV) announced two significant developments. First, the company secured a Standby Equity Purchase Agreement (SEPA) worth up to $30 million over 36 months, with shares priced at 97% of market value. The SEPA proceeds will support R&D programs and corporate activities.
Second, MediciNova achieved its target enrollment in the COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast). The company is also running an Expanded Access Program supported by a $22 million NIH grant. Additionally, patient enrollment is nearly complete for their Phase 2 trial of MN-001 in hypertriglyceridemia and fatty liver disease.
MediciNova (NASDAQ:MNOV) has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel. President and CEO Yuichi Iwaki, MD., Ph.D., and Chief Business Officer David H. Crean, PhD will deliver a corporate overview presentation.
The presentation will be available on-demand starting at 7:00 AM ET on September 5, 2025. Investors can access the live webcast through MediciNova's investor relations website, with the replay remaining available for approximately 90 days. The executives will also be available for one-on-one meetings during the conference.
MediciNova (NASDAQ:MNOV) has announced the successful completion of target enrollment in its Phase 2b/3 COMBAT-ALS clinical trial for MN-166 (ibudilast), a drug candidate being developed for Amyotrophic Lateral Sclerosis (ALS) treatment.
The multi-site trial, conducted across the United States and Canada, represents a crucial milestone in MN-166's development program. According to CEO Dr. Yuichi Iwaki, this achievement reflects strong collaboration between clinical sites, investigators, and patient communities, bringing the company closer to evaluating MN-166's potential impact on ALS patients.
FAQ
What is the current stock price of Medicinova (MNOV)?
What is the market cap of Medicinova (MNOV)?
